Caris Life Sciences, a United States-based molecular science company, announced on Tuesday that it has named Matthew Oberley, MD, PhD, as its new executive medical director.
Dr Oberley joined the company in August 2019 as senior medical director and has functioned as a leading face for Caris' clinical and scientific expertise in the marketplace and research community. Prior to joining Caris, Dr Oberley held roles at the University of Southern California and, most recently, Children's Hospital Los Angeles.
His responsibilities have included managing the company's Medical Science Liaison team and helping connect key oncology research leaders across the country with the large datasets Caris has generated through the Company's molecular profiling technology. In his expanded role, Dr Oberley will manage the company's quality and fidelity of the medical operations facilities to ensure patient safety. Dr Oberley will lead Caris' pathology and genetics teams.
Dexcom highlights new diabetes outcomes and product roadmap at ATTD 2026
Curatis and Neupharma partner to develop corticorelin for peritumoral brain edema in Japan
Samsung Biologics collaborates with Lilly for new Gateway Labs site in Korea
Citius Oncology reports positive topline results from Phase 1 clinical trial of LYMPHIR combination
GenomOncology partners with WeTrials to support CNS cancer clinical trials
Target ALS awards two-year research grant to AcuraStem for advancing therapeutics targeting SYF2
Ascletis reports Phase II weight‑loss results for ASC30 depot formulation
NS Pharma and NCNP report 4.5-year brogidirsen data for DMD treatment
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Koselugo approved in Canada for adults with NF1 and inoperable plexiform neurofibromas
Bristol Myers Squibb reports positive Phase 3 results for oral mezigdomide in multiple myeloma
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
Agilent to acquire Biocare Medical for USD950m to expand pathology portfolio